Neoleukin Investor R&D Showcase - AACR 2020, June 23, 2020

The event will feature an overview of presentations at the American Association for Cancer Research (AACR) Virtual Annual Meeting II as well as commentary from experts in the field of protein design and clinical development of IL-2 therapies.

To RSVP to the webcast please click here!

Speakers will include:

Tech Moves: Microsoft vet Qi Lu steps down at Baidu; Seattle ... Jonathan Drachman, M.D. – Chief Executive Officer of Neoleukin
David_baker_9pg2mw.png David Baker, Ph.D. – Co-founder of Neoleukin and Director of the University of Washington Institute for Protein Design, UW School of Medicine professor of biochemistry and a Howard Hughes Medical Institute investigator
M_Dougan_g49h78.jpg Michael Dougan, M.D., Ph.D. – Assistant Professor of Medicine at Harvard Medical School and an assistant in Medicine, Division of Gastroenterology at Massachusetts General Hospital
nizar_tannir.jpg.resize.280.400.high_ryvvkp.jpg Nizar Tannir, MD, FACP – Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center
RSVP for Event / Log Back in Presenter Access

Additional menu options can be found in the menu bar on the left or at the top.

Neoleukin Therapeutics [NLTX] $440 MM MCap
Lead pro­gram NL-201: is a du­al-act­ing IL-2 and IL-15 ag­on­ist im­munother­a­py for can­cer, de­signed to im­prove tol­er­a­bil­i­ty and ac­tiv­i­ty by elim­i­nat­ing the al­pha re­cep­tor bind­ing in­ter­face (IND com­plet­ed 4Q20). First de no­vo pro­tein ther­a­peu­tic ev­er cre­at­ed. [more in­for­ma­tion]